Classic Hodgkin lymphoma
Information
- Disease name
- Classic Hodgkin lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05179603 | Active, not recruiting | Phase 2 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | December 7, 2021 | January 14, 2025 |
| NCT01771107 | Active, not recruiting | Phase 1/Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | March 7, 2013 | February 28, 2025 |
| NCT02166463 | Active, not recruiting | Phase 3 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | March 19, 2015 | September 22, 2024 |
| NCT02758717 | Active, not recruiting | Phase 2 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | May 13, 2016 | May 13, 2024 |
| NCT03057795 | Active, not recruiting | Phase 2 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | April 3, 2017 | May 30, 2024 |
| NCT03233347 | Active, not recruiting | Phase 2 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | October 13, 2017 | July 8, 2025 |
| NCT03712202 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | November 28, 2018 | September 23, 2024 |
| NCT03907488 | Active, not recruiting | Phase 3 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | August 29, 2019 | April 1, 2025 |
| NCT00654732 | Completed | Phase 2 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | March 19, 2008 | September 5, 2018 |
| NCT06235047 | Completed | Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD) | January 1, 2013 | January 8, 2024 | |
| NCT06465446 | Not yet recruiting | Phase 3 | A Study of IMM01 in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma | June 2024 | July 2029 |
| NCT05949931 | Not yet recruiting | Phase 2 | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | August 2023 | December 2026 |
| NCT06377540 | Not yet recruiting | Phase 2 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | August 1, 2024 | September 1, 2027 |
| NCT06164275 | Recruiting | Phase 2 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | February 6, 2024 | December 31, 2031 |
| NCT05833984 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | May 17, 2022 | November 20, 2024 |
| NCT05955105 | Recruiting | Phase 1/Phase 2 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | July 25, 2023 | July 24, 2026 |
| NCT04788043 | Suspended | Phase 2 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | June 21, 2022 | December 2027 |
- OrphaNumber from OrphaNet (Orphanet)
- 391